Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apoptosis-related changes and endothelial responses in multiple myeloma patients treated with chemotherapy
2012-001813-17Phase 4Terminated
- Sponsor
- Hull University Teaching Hospitals
- Start
- May 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lenalidomide, cyclophosphamide, bortezomib, thalidomide and dexamethasone in multiple myeloma (MM), venous thromboembolism (VTE) and pulmonary embolism (PE), sponsored by Hull University Teaching Hospitals. Primary endpoints: Laboratory evidence of endothelial, platelet, and coagulation cascade disruption and Correlation of thromboembolism with treatment type and laboratory findings. Started May 2012; status: terminated.
02
Drugs
lenalidomidecyclophosphamidebortezomibthalidomidedexamethasone
03
Conditions
multiple myeloma (MM)venous thromboembolism (VTE)pulmonary embolism (PE)
Beyond the preview
Go deeper on 2012-001813-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001813-17.